# 1. Financial Performance ## A. Key Figures * **Revenue:** **₹110.55 Cr** Q1 FY2526 (+50.30% YoY) * EBITDA: ₹14.37 Cr (+12.73% YoY) * **PAT:** **₹10.36 Cr** (+21.47% YoY) * **EBITDA Margin:** 13% Q1 FY2526 * **PAT Margin:** 10% current operations (9–11% range) ## B. Revenue Growth * **Resilient Top-Line Expansion:** Strong double-digit revenue growth achieved despite seasonal headwinds and absence of export contribution, outperforming peers in industrial sectors. * **Growth Trajectory Accelerating:** Revenue surged to ₹377 Cr in FY25 from a base of ₹118 Cr in FY21, reflecting structural scaling and market share gains. * **Next-Gen Capacity to Double Turnover:** First 5,000-ton plant to add **₹270 Cr** in annual revenue, with full ramp-up of two facilities expected to deliver **₹540 Cr** in incremental turnover. * **Project-Led Revenue Recognition:** HFO and specialty gas revenues will be lumpy and better assessed on a quarterly or annual basis due to project execution cycles. ## C. Profit Margins * **Profitability Outpacing Revenue Growth:** EBITDA and PAT grew significantly faster than sales, indicating operating leverage and cost discipline. * **Margin Expansion Ahead:** Current margin compression is transitional; manufacturing scale-up is expected to lift PAT margins to **24%** in dedicated facilities and **18–20%** in high-tech segments like helium and semiconductors. * **Long-Term Margin Target of 20%:** As higher-margin manufacturing assets ramp, combined PAT margin is projected to rise to **17–18%** and stabilize near **20%** at full scale. ## D. Cash Flow Trends * **Persistent Negative Operating Cash Flow:** Operating cash flows net of taxes have been negative for three consecutive years, including ₹45 Cr outflow in FY24 and ₹43 Cr in FY25. * **Growth-Driven Cash Use:** Negative cash flow attributed to aggressive top-line investment and inventory build-up, despite profitability, raising scrutiny on working capital efficiency. --- # 2. Manufacturing & Capacity ## A. Key Figures * **R-32 Plant Capacity:** **10,000 MT** total (2 x 5,000 MT stages) * **Mambattu CapEx Upgrade:** Capacity **doubled to 10 tanks** with hydrocarbon capability * **Project Timeline:** New plant production start expected by **mid-2026** ## B. Plant Expansion * **Strategic Backward Integration:** Entry into core molecule manufacturing establishes **end-to-end control**, enhancing supply security and vertical integration leadership on a pan-India scale. * **First In-House Manufacturing Venture:** The R-32 facility marks the company’s debut in physical production, designed to build **operational credibility** and de-risk future expansions. * **Technological First-Mover Advantage:** Plant design incorporates **300-bar infrastructure from inception**, bypassing legacy constraints and positioning the company alongside global leaders. * **Long-Term Expansion Roadmap:** A pipeline of **multiple future plants** is pre-structured, with 50% planning completed mid-way through prior projects to ensure seamless execution. ## C. Facility Progress * **Advanced Construction Momentum:** Khalapur blending facility has achieved **full civil completion**, with all major equipment ordered and installation pending. * **Revised Operational Timeline:** Mambattu and Khalapur now expected **online by end-November**, delivering only **one quarter of output** in current fiscal with minimal near-term revenue impact. * **Balanced Sheet Recognition:** New plant assets to be reflected from **April onward**, despite project-based revenue recognition delays. ## D. Production Scale-up * **Accelerated Execution Capability:** Project delivery timelines are **50% faster than industry average**, demonstrating superior execution efficiency. * **By-Product Monetization:** Facility design ensures **zero waste stream**, with **hydrochloric acid** and dilute variants sold commercially, adding incremental value. --- # 3. Product & Segment Mix ## A. Key Figures * **Multiuse Products:** **60%** of product portfolio serves multiple applications * **Growth Outlook:** Target markets projected at **strong double-digit CAGRs over the next decade** * **Helium Business Cycle:** New orders expected from **April**, following March tender for **9-month demand** ## B. Refrigerant Blends * **Domestic Manufacturing Push:** Bhilwara facility to produce R-32 and advanced blends, including 410A, 404A, 454B, and 513A, reducing import dependence. * **Advanced Cooling Applications:** HFOs targeted at data centers and semiconductor equipment cooling, though not involved in chip fabrication. ## C. Specialty Gases * **Strategic Market Focus:** Investments directed toward high-growth sectors—semiconductors, solar, fiber optics, and advanced cooling—with India’s nascent ecosystem enabling first-mover advantage. * **SF6 as Niche Insulator:** SF6 is a **segregated product** used in high-voltage power equipment and **medical applications**, including eye surgeries. ## D. Multiuse Applications * **Portfolio Diversification Strategy:** Cyclical demand across segments (e.g., helium’s 2-down/3-up cycle) drives cross-sector deployment to stabilize performance. * **Purity-Driven Customization:** Same base chemicals serve industrial, medical, and electronics sectors based on **grade of purity**, with highest grades required for semiconductor plasma etching and medical use. --- # 4. Supply Chain & Inventory ## A. Key Figures * **Captive Demand:** **2,000–3,000 tons** of R-32 annually * **Freight Cost Volatility:** Costs surged from **$2,000 to $10,000** per shipment to America; tripled for India shipments ## B. Import Dependence * **Strategic Vertical Integration:** Company aims to **reduce import reliance** by bringing R-32 manufacturing in-house to meet full captive demand. * **Geopolitical Risk Mitigation:** Inventory buffers are maintained to counter supply disruptions in the South China Sea from geopolitical, climatic, and freight risks. ## C. Inventory Strategy * **Tactical Inventory Management:** Current stock levels are **strategically held by choice**, not overstocking, ensuring supply reliability and insulation from price spikes. * **Value Realization & Market Timing:** Past inventory buildup before antidumping duties led to **significant turnover gains**; company leverages stockpiles to avoid peak pricing. * **Low-Risk Holding Model:** No loss or wastage on inventory, making it a **high-reward, low-risk** strategy amid volatile cycles. ## D. Raw Material Sourcing * **Import-Dependent Processing Model:** Gas molecules like R-32 are **not manufactured** but imported in bulk and processed in-house through quality control and formulation. * **Partial Supply Chain Independence:** Even with domestic R-32 production, **reliance on imported fluorospar** (e.g., from Vietnam, Mexico) limits full self-sufficiency. --- # 5. Demand & Pricing Trends ## A. Key Figures * **R-32 Usage:** **10,000–15,000 tons** (current standalone AC use) · **>10,000 tons** R-134A in use * **HFO Blends R-32 Content:** **50–60%** R-32 in next-gen blends · **50%** in R-513A * **HFO Sales Volume:** **300–400 tons** sold in India to date * **Market Structure:** **85%** of aftermarket accessible without OEM approval · **30–40%** sales to OEMs, **60–70%** to aftermarket * **Cylinder Efficiency:** **7 m³** at 200 bar · **10–11 m³** at 300 bar (same 50L cylinder) ## B. HFO Adoption * **Strategic Shift to HFOs:** Accelerated transition from high-GWP R-32 (600) to low-GWP HFO blends like **R-454B (300 GWP)** driven by global and domestic environmental regulations. * **R-32 Remains Core Input:** Despite declining standalone use, **total R-32 demand set to rise significantly** due to its critical role in HFO blends, boosting internal consumption over exports. * **In-House R-32 Manufacturing Essential:** Vertical integration of R-32 production is key to securing cost-efficient, reliable supply as HFO capacity scales. * **India as HFO Growth Hub:** Domestic data localization policies (e.g., Amazon data centers) and MNC investments (e.g., Reliance) are driving early HFO adoption, particularly in southern India. * **Duopoly in HFO Market:** Only two players—Rustomji’s company and Chemours—currently supply HFOs nationwide, signaling high barriers to entry and pricing power. ## C. Aftermarket Pricing * **Flexible Pricing Advantage:** Aftermarket, representing the majority of demand, operates on a **15-day spot pricing model**, enabling rapid response to supply-demand shifts and margin optimization. * **300-Bar Fill as Competitive Edge:** Adoption of **300-bar cylinder filling** (vs. standard 200 bar) increases gas load by ~57%, drastically improving logistics efficiency and bid competitiveness for offshore and defense clients. * **Antidumping Duty as Price Catalyst:** Sharp revenue growth in 2021–2022 was directly tied to **R-32 antidumping duties**, which doubled prices and reshaped import dynamics. * **Seasonal Volatility Observed:** April showed strong momentum, but performance weakened post-monsoon onset, highlighting seasonality in demand patterns. ## D. OEM Contracts * **Shift Away from Annual Contracts:** In current volatile forex environment, **monthly/quarterly pricing models favored** over annual contracts due to inability to pass through dollar fluctuations. * **OEM Supply Mix Stable:** Roughly one-third of sales supplied under OEM contracts, supported by full approvals across major manufacturers. --- # 6. Risks & Regulatory Shifts ## A. Monsoon & Geopolitical Disruptions * **Severe Operational Halt:** War outbreak in April triggered a complete standstill in industry activity, halting projects akin to the COVID period. * **Compounded Seasonal Disruption:** Early monsoon onset in May and unseasonal rains washed out the entire season, flooding a below-ground-level site adjacent to a lake and delaying critical soil work until July. * **Project Timeline Resilience:** Management distinguishes between minor delays (e.g., November to December) and material slippage (e.g., to next August), with the latter signaling operational concern. ## B. Patent-Driven Competitive Moat * **Unmatched Reliability Record:** Stallion has maintained 100% supply continuity over 30 years, serving as the sole supplier during national shortages in 2005, 2010, 2017, and 2021. * **Accelerated Market Access:** Due to proven trust, **85% of qualification criteria are waived**, reducing onboarding to only lab testing and trials, with full product qualification typically completed in **1–2 months**. * **Exclusive HFO Rights:** The company holds exclusive rights to sell HFOs in India via a 20-year partnership with Honeywell, while patent barriers prevent any local Indian HFC manufacturers from producing or selling HFOs. ## C. China Dependency & Strategic Shifts * **Deep Global Dependence:** China controls **85% of global fluorochemicals** and dominates critical mineral supply chains, enabling unilateral price influence and creating strategic vulnerabilities. * **De Facto Sourcing Reality:** Even U.S.-branded imports (e.g., Honeywell, Kenura) are largely manufactured in China, reinforcing dependency despite origin labels. * **Structural Import Reliance:** India has lost domestic capacity in key sectors—e.g., Morbi’s tile industry—now fully dependent on Chinese imports. * **Strategic Diversification Underway:** Government-backed China-plus-one initiatives are advancing alternate supply chains, with a focus on local manufacturing and non-Chinese sourcing, though full import elimination would undermine competitiveness. * **Chinese Pricing Agility:** Faced with pricing constraints, Chinese firms shift costs to freight—now a sector they significantly control—demonstrating adaptive trade strategies. --- # 7. Guidance & Outlook ## A. Key Figures * **Revenue Growth Outlook:** **30–35%** annual CAGR targeted over next 3 years · **INR 100 Cr** incremental revenue expected in FY26 and FY27 each * **Turnover Target:** Aiming to **cross INR 2,500 Cr** by FY29 through phased expansions * **PAT Margin (Manufacturing Segment):** Target **over 24%** · **17–18%** group average PAT margin expected by 2026 ## B. Revenue Projections * **Ambitious but Non-Binding Targets:** Management emphasizes aspirational nature of **INR 2,500 Cr** FY29 goal, focusing instead on internal milestones and execution discipline. * **Multi-Year Growth Trajectory:** Revenue growth expected to accelerate in **multiples**, not linearly, driven by full commissioning of **Mambattu, Khalapur, and Bhilwara** plants from 2026 onward. * **Near-Term Momentum:** Q4 FY25 targeted for **30% YoY growth**, consistent with historical delivery track record and conservative forecasting bias. * **Phased Revenue Ramp:** Initial revenue post-commissioning expected in Q1, with **significant uplift in 2026** due to tender-based, high-value product contracts. ## C. Margin Targets * **High-Margin Expansion:** New manufacturing and specialty gases (helium, semiconductor) expected to drive **material margin uplift**, with PAT margins targeted above 24%. * **Scalability Potential:** EBITDA margins could approach **30%** at full scale, though formal guidance awaits operational validation. ## D. Project Timelines * **2026 as Inflection Year:** Commercial operations set to begin at **Bhilwara, Mambattu, Khalapur, and Rajasthan** plants, marking a step-change in capacity and revenue generation. * **Timeline Resilience:** Despite **one-year delay** from IPO-related setbacks, core projects remain on track with only **minimal (one-month) risk at Mambattu** due to licensing. * **Funding Flexibility:** CapEx currently self-funded; future options include **debt, rights issue, or preferential equity**, with a **1-year probation window** to secure higher funding capacity. * **Seasonality Awareness:** Weakest quarters are **July–September** and **April–June**, with strongest performance historically in **H2 (Oct–Mar)**.